Logos Global Management LP Sells 1,744,960 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)

Logos Global Management LP lowered its stake in Astria Therapeutics, Inc. (NASDAQ:ATXS) by 77.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 500,000 shares of the biotechnology company’s stock after selling 1,744,960 shares during the period. Logos Global Management LP owned approximately 0.91% of Astria Therapeutics worth $4,550,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Quest Partners LLC increased its stake in Astria Therapeutics by 3,310.6% in the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 3,112 shares during the period. Ameritas Investment Partners Inc. grew its holdings in shares of Astria Therapeutics by 135.6% in the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 2,861 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new position in shares of Astria Therapeutics in the first quarter worth $200,000. Hsbc Holdings PLC bought a new stake in Astria Therapeutics during the 2nd quarter valued at $171,000. Finally, American International Group Inc. raised its holdings in Astria Therapeutics by 49.4% during the 1st quarter. American International Group Inc. now owns 24,565 shares of the biotechnology company’s stock valued at $346,000 after buying an additional 8,122 shares during the last quarter. Institutional investors own 98.98% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on ATXS shares. HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research report on Friday. Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. TD Cowen began coverage on Astria Therapeutics in a report on Monday, July 29th. They issued a “buy” rating and a $35.00 price objective for the company. Oppenheimer lifted their price objective on Astria Therapeutics from $25.00 to $26.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 13th. Finally, Wedbush restated an “outperform” rating and set a $22.00 target price on shares of Astria Therapeutics in a report on Tuesday, August 13th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $25.20.

Astria Therapeutics Price Performance

Shares of ATXS opened at $11.01 on Tuesday. The company has a 50-day simple moving average of $11.32 and a two-hundred day simple moving average of $10.78. The firm has a market capitalization of $604.59 million, a PE ratio of -4.75 and a beta of 0.71. Astria Therapeutics, Inc. has a one year low of $4.26 and a one year high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last released its earnings results on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). Analysts expect that Astria Therapeutics, Inc. will post -1.66 EPS for the current fiscal year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.